KR100757764B1 - 내성 유방암 치료에서의 풀베스트란트의 용도 - Google Patents

내성 유방암 치료에서의 풀베스트란트의 용도 Download PDF

Info

Publication number
KR100757764B1
KR100757764B1 KR1020027013366A KR20027013366A KR100757764B1 KR 100757764 B1 KR100757764 B1 KR 100757764B1 KR 1020027013366 A KR1020027013366 A KR 1020027013366A KR 20027013366 A KR20027013366 A KR 20027013366A KR 100757764 B1 KR100757764 B1 KR 100757764B1
Authority
KR
South Korea
Prior art keywords
treatment
fulvestrant
lesions
breast cancer
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027013366A
Other languages
English (en)
Korean (ko)
Other versions
KR20030007501A (ko
Inventor
썰리만비트
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100757764(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20030007501A publication Critical patent/KR20030007501A/ko
Application granted granted Critical
Publication of KR100757764B1 publication Critical patent/KR100757764B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020027013366A 2000-04-05 2001-04-02 내성 유방암 치료에서의 풀베스트란트의 용도 Expired - Lifetime KR100757764B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0008172.9 2000-04-05
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number Publication Date
KR20030007501A KR20030007501A (ko) 2003-01-23
KR100757764B1 true KR100757764B1 (ko) 2007-09-12

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027013366A Expired - Lifetime KR100757764B1 (ko) 2000-04-05 2001-04-02 내성 유방암 치료에서의 풀베스트란트의 용도

Country Status (28)

Country Link
US (2) US20030158166A1 (cg-RX-API-DMAC10.html)
EP (2) EP1272195B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003528919A (cg-RX-API-DMAC10.html)
KR (1) KR100757764B1 (cg-RX-API-DMAC10.html)
CN (1) CN1431905A (cg-RX-API-DMAC10.html)
AT (1) ATE306270T1 (cg-RX-API-DMAC10.html)
AU (2) AU4437201A (cg-RX-API-DMAC10.html)
BR (1) BR0109789A (cg-RX-API-DMAC10.html)
CA (1) CA2403608A1 (cg-RX-API-DMAC10.html)
CH (1) CH1272195H1 (cg-RX-API-DMAC10.html)
CZ (1) CZ303096B6 (cg-RX-API-DMAC10.html)
DE (1) DE60113975T2 (cg-RX-API-DMAC10.html)
DK (1) DK1272195T3 (cg-RX-API-DMAC10.html)
EE (1) EE05026B1 (cg-RX-API-DMAC10.html)
ES (1) ES2248300T3 (cg-RX-API-DMAC10.html)
GB (1) GB0008172D0 (cg-RX-API-DMAC10.html)
HU (1) HU230064B1 (cg-RX-API-DMAC10.html)
IL (2) IL151932A0 (cg-RX-API-DMAC10.html)
IS (1) IS2869B (cg-RX-API-DMAC10.html)
MX (1) MXPA02009744A (cg-RX-API-DMAC10.html)
NO (1) NO329949B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ539603A (cg-RX-API-DMAC10.html)
PL (1) PL201175B1 (cg-RX-API-DMAC10.html)
RU (1) RU2265438C2 (cg-RX-API-DMAC10.html)
SK (1) SK287779B6 (cg-RX-API-DMAC10.html)
UA (1) UA80388C2 (cg-RX-API-DMAC10.html)
WO (1) WO2001074366A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200207538B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1406662A1 (en) * 2001-07-07 2004-04-14 AstraZeneca AB Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
WO2007062093A2 (en) * 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
RU2013154048A (ru) * 2011-05-09 2015-06-20 Юниверсити Оф Вирджиния Пэтент Фаундейшн Композиции и способы лечения рака
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3210276A1 (en) * 2020-02-29 2021-09-02 Frances E. Carr Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bordie et al.(1999, Endocrine-Related Cancer, v.6 p. 205-210)

Also Published As

Publication number Publication date
NO329949B1 (no) 2011-01-31
ZA200207538B (en) 2003-12-19
KR20030007501A (ko) 2003-01-23
AU2001244372B2 (en) 2006-02-16
NO20024735D0 (no) 2002-10-02
US20110183949A1 (en) 2011-07-28
IL151932A (en) 2007-07-04
EE05026B1 (et) 2008-06-16
CN1431905A (zh) 2003-07-23
PL357936A1 (en) 2004-08-09
EP1272195B1 (en) 2005-10-12
AU4437201A (en) 2001-10-15
IS6576A (is) 2002-10-01
GB0008172D0 (en) 2000-05-24
HUP0300339A2 (hu) 2003-06-28
WO2001074366A1 (en) 2001-10-11
DE60113975D1 (de) 2006-02-23
CZ20023309A3 (cs) 2003-02-12
PL201175B1 (pl) 2009-03-31
BR0109789A (pt) 2003-01-21
ES2248300T3 (es) 2006-03-16
DE60113975T2 (de) 2006-06-22
HUP0300339A3 (en) 2009-01-28
SK14292002A3 (sk) 2003-08-05
HK1051498A1 (en) 2003-08-08
JP2003528919A (ja) 2003-09-30
NZ539603A (en) 2008-02-29
HU230064B1 (hu) 2015-06-29
EP1272195A1 (en) 2003-01-08
CA2403608A1 (en) 2001-10-11
SK287779B6 (sk) 2011-09-05
ATE306270T1 (de) 2005-10-15
DK1272195T3 (da) 2006-01-16
MXPA02009744A (es) 2004-02-26
US20030158166A1 (en) 2003-08-21
EP1586323A1 (en) 2005-10-19
IL151932A0 (en) 2003-04-10
CH1272195H1 (cg-RX-API-DMAC10.html) 2019-10-15
RU2265438C2 (ru) 2005-12-10
UA80388C2 (en) 2007-09-25
CZ303096B6 (cs) 2012-04-04
NO20024735L (no) 2002-11-27
IS2869B (is) 2014-03-15
EE200200574A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
Paridaens et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
KIANG et al. Tamoxifen (antiestrogen) therapy in advanced breast cancer
Ellis et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Bajetta et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
Reginster et al. Minimal levels of serum estradiol prevent postmenopausal bone loss
Emons et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie
Baumann et al. Estrogen receptor modulators and down regulators: Optimal use in postmenopausal women with breast cancer
Lee et al. Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double‐Blind, Placebo‐Controlled Phase II Trial
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
Hirvonen et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen?
RU2320339C2 (ru) Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы
HRP20120084A2 (hr) FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE
EP4493185A1 (en) Treatment of breast cancer with amcenestrant
Manni et al. Transsphenoidal hypophysectomy in breast cancer. Evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth.
Homesley et al. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women
KR20070006543A (ko) 확장된 경피 피임제 투약 계획
Williams et al. Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer.
Zilembo et al. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer
Howell et al. Endocrine therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060331

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070416

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070807

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070905

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070906

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction
PR1001 Payment of annual fee

Payment date: 20100827

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110830

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120821

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120821

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130820

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130820

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140825

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140825

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150818

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150818

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160818

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170818

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20180816

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20200819

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20211002

Termination category: Expiration of duration